22 July 2022

MEMORANDUM FOR: KARINE JEAN-PIERRE
ASSISTANT TO THE PRESIDENT AND
WHITE HOUSE PRESS SECRETARY

FROM: KEVIN C. O’CONNOR, D.O., FAAFP
PHYSICIAN TO THE PRESIDENT

SUBJECT: President Biden SARS-CoV-2 Update

President Biden completed his first full day of PAXLOVID last night. His symptoms have improved. He did mount a temperature yesterday evening to 99.4°F, which responded favorably to acetaminophen (TYLENOL). His temperature has remained normal since then. His symptoms remain characterized as rhinorrhea ("runny nose") and fatigue, with an occasional non-productive, now "loose" cough. His voice is deeper this morning. His pulse, blood pressure, respiratory rate and oxygen saturation remain entirely normal, on room air.

The President is tolerating treatment well. We will continue PAXLOVID as planned. His symptoms will be treated supportively with oral hydration, acetaminophen (TYLENOL), and the albuterol inhaler that he uses as needed. His apixaban (ELIQUIS) and rosuvastatin (Crestor) are being held during PAXLOVID treatment and for several days after his last dose. During this time, it is reasonable to add low dose aspirin as an alternative type of blood thinner.

As I stated previously, the President is fully vaccinated and twice-boosted, so I anticipate that he will respond favorably, as most maximally protected patients do. There has been nothing in the course of his illness thus far which gives me cause to alter that initial expectation. Early use of PAXLOVID provides additional protection against severe disease. He will isolate in accordance with Centers for Disease Control and Prevention (CDC) recommendations, and we will continue to monitor him closely, during this very common outpatient treatment regimen.

As promised, I will keep your office updated with any changes in his condition or treatment plan.

Respectfully submitted,

Kevin C. O’Connor, D.O., FAAFP
Physician to the President
Associate Professor, The George Washington University School of Medicine & Health Sciences